Search results for "fibrinolysis"

showing 10 items of 82 documents

Impact of prehospital delay on mortality in patients with acute myocardial infarction treated with primary angioplasty and intravenous thrombolysis.

2001

Abstract Background In patients with acute myocardial infarction treated with thrombolysis, longer times to treatment are associated with increasingly worse clinical outcome. This relation may be different for treatment with primary angioplasty. Methods We analyzed the pooled data of the German acute myocardial infarction registries Maximal Individual Therapy in Acute Myocardial Infarction (MITRA) and Myocardial Infarction Registry (MIR) to determine the influence of prehospital delays on hospital mortality rates. Primary angioplasty was performed in 1063 patients and thrombolysis in 7552 patients. Results In patients treated with thrombolysis, in-hospital time to treatment was constantly 3…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentTime to treatmentPrimary angioplastyMyocardial InfarctionStatistics NonparametricInternal medicineFibrinolysismedicineHumansIn patientThrombolytic TherapyMyocardial infarctionHospital MortalityProspective StudiesRegistriesChemotherapyChi-Square Distributionbusiness.industryMortality rateThrombolysisMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeCardiologyFemaleCardiology and Cardiovascular MedicinebusinessAngioplasty BalloonAmerican heart journal
researchProduct

Postoperative Reduction of Fibrinolysis as a Prognostic Factor of Fatal Outcome

2001

For the resection of an esophagus carcinoma a mortality rate of 2 to 30% was described, It is still unclear whether an abdominothoracic or transhiatal intervention is superior regarding the outcome. To investigate the prognostic value of fibrinolytic markers, plasmin-α2-antiplasmin (PAP) and D-dimer (DD) values were determined daily in the early postoperative period for 11days. In addition, the course of PAP and DD concentrations was compared with the method of esophagectomy. Of the 28 patients enclosed in the study, 5 died between day 10 and day 34 owing to adult respiratory distress syndrome and septicemia. The PAP and DD concentrations increased in survivors after surgery until day 5 an…

AdultMalemedicine.medical_specialtyTime FactorsFatal outcomeEsophageal Neoplasmsmedicine.medical_treatmentReference range030204 cardiovascular system & hematologySensitivity and SpecificityGastroenterologyFibrin Fibrinogen Degradation Products03 medical and health sciences0302 clinical medicineInternal medicineFibrinolysisD-dimermedicineHumansFibrinolysinPostoperative PeriodSurvival rateAgedalpha-2-AntiplasminRespiratory distressbusiness.industryFibrinolysisMortality rateHematologyGeneral MedicineMiddle AgedPrognosisAntifibrinolytic AgentsSurgeryEsophagectomySurvival RateROC CurveEsophagectomyFemalebusinessBiomarkers030215 immunologyClinical and Applied Thrombosis/Hemostasis
researchProduct

Five-Year Survival in Patients With ST-Segment–Elevation Myocardial Infarction According to Modalities of Reperfusion Therapy

2014

Background— Although primary percutaneous coronary intervention (pPCI) is the preferred reperfusion method for ST-segment–elevation myocardial infarction, it remains difficult to implement in many areas, and fibrinolytic therapy is still widely used. Methods and Results— We assessed 5-year mortality in patients with ST-segment–elevation myocardial infarction from the French Registry of Acute ST-Elevation or Non-ST Elevation Myocardial Infarction (FAST-MI) 2005 according to use and type of reperfusion therapy. Of 1492 patients with ST-segment–elevation myocardial infarction with a first call ≤12 hours from onset, 447 (30%) received fibrinolysis (66% prehospital; 97% with subsequent angiogra…

Malemedicine.medical_specialtymedicine.medical_treatmentMyocardial InfarctionMyocardial Reperfusion030204 cardiovascular system & hematologyCohort Studies03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicineReperfusion therapyFibrinolytic AgentsPhysiology (medical)Internal medicineFibrinolysisHumansMedicineST segmentRegistries030212 general & internal medicineMyocardial infarctionAgedAged 80 and overbusiness.industryST elevationHazard ratioPercutaneous coronary interventionMiddle Agedmedicine.disease3. Good healthSurgerySurvival RateTreatment OutcomeConventional PCICardiologyFemaleFranceCardiology and Cardiovascular MedicinebusinessCirculation
researchProduct

Endovascular management of the deep venous thrombosis: A new challenging role for the endovascular specialist in 2020

2020

Over the last years, the endovascular approach to the management of the acute and chronic deep vein thrombosis (DVT) has gained more and more attention from the scientific community. DVT is the third most common cardiovascular disease after coronary heart disease and stroke, with classic treatment based on anticoagulation. Recent evidences have highlighted the risk of postthrombotic syndrome as high as 30%-50% in proximal ilio-femoral lesions, with irreversible clinical symptoms and impact on the quality of life of the population. Since 2000s, the new concept of thrombus removal in the acute phase has been supported by the introduction of different techniques based on the endovascular ablat…

medicine.medical_specialty[SDV]Life Sciences [q-bio]medicine.medical_treatmentDeep veinPopulationDiseaseIliac Vein030204 cardiovascular system & hematologyPostthrombotic Syndrome03 medical and health sciences0302 clinical medicineFibrinolysismedicineHumansThrombolytic TherapyRadiology Nuclear Medicine and imagingcardiovascular diseases030212 general & internal medicineThrombusIntensive care medicineeducationStrokeComputingMilieux_MISCELLANEOUSVenous Thrombosiseducation.field_of_studybusiness.industryEndovascular ProceduresGeneral Medicinemedicine.diseaseThrombosis3. Good healthVenous thrombosisTreatment Outcomemedicine.anatomical_structureQuality of LifeCardiology and Cardiovascular MedicinebusinessCatheterization and Cardiovascular Interventions
researchProduct

Plasma levels of inflammatory and thrombotic/fibrinolytic markers in acute ischemic strokes: Relationship with TOAST subtype, outcome and infarct site

2009

BACKGROUND: The aim of our study was to evaluate in patients with acute ischemic stroke the relationship between immuno-inflammatory variables, clinical outcome and infarct site. MATERIALS AND METHODS: We evaluated plasma levels of IL-1beta, TNF-alpha, IL-6 and IL-10, E-selectin, P-selectin, sICAM-1 ,sVCAM-1 vWF, TPA and PAI-1. RESULTS: Patients with cardioembolic subtype showed significantly higher median plasma levels of TNF-alpha, IL-6, IL-1beta whereas the lacunar subtype showed significantly lower median plasma levels of TNF-alpha, IL-6 and IL-1beta. CONCLUSIONS: A significant association was noted between the severity of neurological deficit at admission, the diagnostic subtype and so…

Malemedicine.medical_specialtystroke TOAST subtypeImmunologyInflammationGastroenterologyBrain IschemiaInternal medicinemedicineHumansImmunology and AllergyIn patientAcute ischemic strokeStrokeAgedNeurological deficitAged 80 and overbusiness.industryFibrinolysisIschemic strokesCerebral InfarctionPlasma levelsMiddle Agedmedicine.diseaseStrokeNeurologyPhysical therapyFemaleNeurology (clinical)Inflammation MediatorsIntracranial Thrombosismedicine.symptombusinessBiomarkersJournal of Neuroimmunology
researchProduct

The importance of diagnosing the Polycystic Ovary Syndrome

2000

The polycystic ovary syndrome (PCOS) is an extremely common disorder that occurs in 4% to 7% of women of reproductive age. Although PCOS is known to be associated with reproductive morbidity and increased risk for endometrial cancer, diagnosis is especially important because PCOS is now thought to increase metabolic and cardiovascular risks. These risks are strongly linked to insulin resistance and are compounded by the common occurrence of obesity, although insulin resistance and its associated risks are also present in nonobese women with PCOS. Women with PCOS are at increased risk for impaired glucose tolerance, type 2 diabetes mellitus, and hypertension. Cardiovascular disease is believ…

medicine.medical_specialtyendocrine system diseasesPhysiologyType 2 diabetesImpaired glucose toleranceInsulin resistanceDiabetes mellitusInternal medicineGlucose IntoleranceInternal MedicinemedicineHumansRisk factorbusiness.industryFibrinolysisnutritional and metabolic diseasesType 2 Diabetes MellitusGeneral Medicinemedicine.diseaseObesityPolycystic ovaryLipidsfemale genital diseases and pregnancy complicationsEndocrinologyCardiovascular DiseasesFemalepolycystic ovary syndrome cardiovascular risk insuline resistanceInsulin ResistancebusinessHyperandrogenismAnovulationPolycystic Ovary Syndrome
researchProduct

ABNORMALLY HIGH THROMBOXANE BIOSYNTHESIS IN HOMOZYGOUS HOMOCYSTINURIA. EVIDENCE FOR PLATELET INVOLVEMENT AND PROBUCOL-SENSITIVE MECHANISM.

1993

Homocystinuria due to homozygous cystathionine beta-synthase deficiency is an inborn error of metabolism characterized by a high incidence of thrombosis and premature atherosclerosis. We evaluated TXA2 biosynthesis in vivo and several in vitro tests of platelet function in 11 homocystinuric patients and 12 healthy controls. In vitro, patients' platelet aggregation was within control values as were TXB2 formation, fibrinogen binding, and ATP secretion in response to thrombin. In contrast, the urinary excretion of 11-dehydro-TXB2, a major enzymatic derivative of TXA2, was > 2 SD of controls in all patients (1,724 +/- 828 pg/mg creatinine, mean +/- SD, in patients vs. 345 +/- 136 in controls, …

AdultBlood PlateletsMalemedicine.medical_specialtyAdolescentPlatelet AggregationThromboxaneProbucolHomocystinuriaInternal medicinemedicineHumansPlateletPlatelet activationChildBlood CoagulationbiologyAspirinChemistryFibrinolysisHomozygoteFibrinogen bindingThromboxanesGeneral Medicinemedicine.diseaseCystathionine beta synthaseEndocrinologyProbucolbiology.proteinlipids (amino acids peptides and proteins)FemaleHomocystinuriaCyclooxygenasemedicine.drugcirculatory and respiratory physiologyResearch Article
researchProduct

Murine tissue factor disulfide mutation causes a bleeding phenotype with sex specific organ pathology and lethality.

2019

Tissue factor is highly expressed in sub-endothelial tissue. The extracellular allosteric disulfide bond Cys186-Cys209 of human tissue factor shows high evolutionary conservation and in vitro evidence suggests that it significantly contributes to tissue factor procoagulant activity. To investigate the role of this allosteric disulfide bond in vivo, we generated a C213G mutant tissue factor mouse by replacing Cys213 of the corresponding disulfide Cys190-Cys213 in murine tissue factor. A bleeding phenotype was prominent in homozygous C213G tissue factor mice. Pre-natal lethality of 1/3rd of homozygous offspring was observed between E9.5 and E14.5 associated with placental hemorrhages. After b…

Malemedicine.medical_specialtyOffspring610 Medicine & healthHemorrhage030204 cardiovascular system & hematologyBiologymedicine.disease_causeArticleThromboplastin11459 Center for Molecular Cardiology03 medical and health sciencesTissue factorArterial Thrombosis; Blood Coagulation and Fibrinolysis; Disorders of Coagulation and FibrinolysisMice0302 clinical medicineIn vivoPregnancyInternal medicinemedicineExtracellularAnimalsDisulfidesMutationHematologyPhenotypeIn vitroEndocrinologyPhenotype10036 Medical Clinic10076 Center for Integrative Human PhysiologyHemostasisMutation10209 Clinic for CardiologyFemale030215 immunologyHaematologica
researchProduct

Improvement of fibrinolysis and plasma lipoprotein levels induced by gemfibrozil in hypertriglyceridemia.

1995

A randomized double-blind study was carried out with gemfibrozil (600 mg b.i.d.) vs placebo in 20 patients (twelve males and eight females, age 52 +/- 3 years, BMI 24.2 +/- 0.4) suffering from primary hypertriglyceridemia (Fredrickson's type IV). Each group was treated for a 12 week period with gemfibrozil (n = 10) or placebo (n = 10) patients) in a double-blind fashion. Total cholesterol, HDL-cholesterol (HDL-C) and its subfractions (HDL2-C and HDL3-C), blood glucose, Apolipoproteins A1 and B, fibrinogen, plasminogen, factor VII, t-PA:Ag and PAI activity pre- and post-venous occlusion (VO) were determined. In the gemfibrozil-treated group a significant decrease of total cholesterol and tri…

Malemedicine.medical_specialtymedicine.medical_treatmentLipoproteinsFibrinogenchemistry.chemical_compoundDouble-Blind MethodInternal medicineFibrinolysismedicineGemfibrozilHumansTriglyceridesApolipoproteins BHypertriglyceridemiaTriglycerideApolipoprotein A-Ibusiness.industryCholesterolFibrinolysisHypertriglyceridemiaReverse cholesterol transportCholesterol HDLFibrinogenPlasminogenHematologyGeneral MedicineFactor VIIMiddle Agedmedicine.diseaseEndocrinologyCholesterolchemistryTissue Plasminogen Activatorlipids (amino acids peptides and proteins)FemaleGemfibrozilbusinessLipoproteinmedicine.drugBlood coagulationfibrinolysis : an international journal in haemostasis and thrombosis
researchProduct

Use of Thromboelastography in severe sepsis a case-control Study

2011

Thromboelastography (TEG) is a global test of coagulation that records the viscoelastic changes in blood during clot formation. Cardiosurgery and liver transplantation are established fields of application for TEG. Severe sepsis is often characterized by an imbalance of the haemostatic equilibrium between clot formation and fibrinolysis in favor of a procoagulant status, especially in the first phase. A hypocoagulant status due to coagulation factor consumption could occur later. In spite of this, the correlation between TEG and sepsis is not clearly established. Moreover, there are doubts about which TEG-detected variable is best correlated with sepsis. The aim of this study is to clarify …

medicine.medical_specialtymedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentCase-control studyThromboelastography Severe Sepsis Septic ShockSettore MED/41 - AnestesiologiaLiver transplantationCritical Care and Intensive Care Medicinemedicine.diseaseClot formationThromboelastographySurgerySepsisCoagulationInternal medicineFibrinolysisPoster PresentationmedicineCardiologybusinessSevere sepsis
researchProduct